Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 88.1% in March

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 4,900 shares, a decrease of 88.1% from the February 29th total of 41,100 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 45,400 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Estrella Immunopharma

A hedge fund recently bought a new stake in Estrella Immunopharma stock. ATW Spac Management LLC purchased a new stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned about 0.11% of Estrella Immunopharma as of its most recent SEC filing. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Trading Down 0.8 %

Shares of ESLA stock traded down $0.01 during trading hours on Thursday, reaching $1.24. The stock had a trading volume of 20,903 shares, compared to its average volume of 46,074. The stock has a fifty day simple moving average of $1.12. Estrella Immunopharma has a 12 month low of $0.86 and a 12 month high of $33.00.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.03) earnings per share for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.